Literature DB >> 6730489

Outpatient theophylline determinations.

A R Knodel, H D Covelli, J F Beekman.   

Abstract

The indications and usefulness of outpatient serum theophylline determinations were prospectively evaluated by doing 151 of these studies in 137 consecutive cases of chronic obstructive pulmonary disease. We found that evaluations were done for the following three groups of indications: group A, worsening bronchospasm; group B, stable asymptomatic cases, and group C, symptoms suggesting theophylline toxicity. When the three clinical groups were compared for frequency of nontherapeutic values, only an increased frequency of subtherapeutic values in patients with bronchospasm (group A) was significant (P<.01). Increasing the dosage up to 15 mg per kg of body weight a day while theophylline determinations are pending appears to be safe in this group of patients. Toxic symptoms were rarely associated with concentrations greater than 20 mug per ml (3/13) and infrequently occurred in patients with concentrations greater than 20 mug per ml (3/29). Nontherapeutic theophylline values did not always result in an adjustment of theophylline dosage. This was influenced by a correlation of symptoms, timing of the theophylline determination and the use of other bronchodilators.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6730489      PMCID: PMC1011079     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  10 in total

1.  Dosage of theophylline in bronchial asthma.

Authors:  K M Piafsky; R I Ogilvie
Journal:  N Engl J Med       Date:  1975-06-05       Impact factor: 91.245

2.  Study of theophylline plasma levels after oral administration of new theophylline compounds.

Authors:  M TURNER-WARWICK
Journal:  Br Med J       Date:  1957-07-13

3.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

4.  Intrapatient variability in theophylline kinetics.

Authors:  P D Walson; R C Strunk; L M Taussig
Journal:  J Pediatr       Date:  1977-08       Impact factor: 4.406

5.  Clinical experience with theophylline. Relarionships between dosage, serum concentration, and toxicity.

Authors:  M H Jacobs; R M Senior; G Kessler
Journal:  JAMA       Date:  1976-05-03       Impact factor: 56.272

6.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

7.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

8.  Oral aminophylline therapy. Increased dosage requirements in children.

Authors:  D E Zaske; K W Miller; E L Strem; S Austrian; P B Johnson
Journal:  JAMA       Date:  1977-04-04       Impact factor: 56.272

9.  Guide to oral theophylline therapy for the treatment of chronic asthma.

Authors:  L Hendeles; M Weinberger; R Wyatt
Journal:  Am J Dis Child       Date:  1978-09

10.  Aminophylline therapy in children: guidelines for dosage.

Authors:  P Rangsithienchai; R W Newcomb
Journal:  J Pediatr       Date:  1977-08       Impact factor: 4.406

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.